Everything below concerns reversed-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | About 1419.5 Da | Calculated from the fifteen-residue sequence |
| Residue count | 15 amino acids | Single-letter sequence GEPPPGKPADDAGLV |
| Compound class | Synthetic peptide | Produced by solid-phase synthesis |
| Synonyms | BPC 157; pentadecapeptide BPC 157 | Naming varies across suppliers and papers |
| Appearance | White to off-white powder | Typical form of the lyophilized material |
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
Mevalonate synthesis begins with the beta-ketothiolase-catalyzed Claisen condensation of two molecules of acetyl-CoA to produce acetoacetyl CoA. The following reaction involves the joining of acetyl-CoA and acetoacetyl-CoA to form HMG-CoA, a process catalyzed by HMG-CoA synthase. In the final step of mevalonate biosynthesis, HMG-CoA reductase, an NADPH-dependent oxidoreductase, catalyzes the conversion of HMG-CoA into mevalonate, which is the primary regulatory point in this pathway. Mevalonate serves as the precursor to isoprenoid groups that are incorporated into a wide variety of end-products, including cholesterol in humans.
In principle, mandating countries were only supposed to hold these former colonies "in trust" for their inhabitants, until they were sufficiently prepared for their own self-determination. Under these terms, Japan, Australia, and New Zealand were granted the German Pacific islands, and the Union of South Africa received South West Africa. It soon became apparent the South African government had interpreted the mandate as a veiled annexation. In September 1922, South African Prime Minister Jan Smuts testified before the League of Nations Mandate Commission that South West Africa was being fully incorporated into the Union and should be regarded, for all practical purposes, as a fifth province of South Africa. According to Smuts, this constituted "annexation in all but in name". Throughout the 1920s and 1930s, the League of Nations complained that of all the mandatory powers South Africa was the most delinquent with regards to observing the terms of its mandate. The Mandate Commission vetoed a number of ambitious South African policy decisions, such as proposals to nationalise South West African railways or alter the preexisting borders. Sharp criticism was also leveled at South Africa's disproportionate spending on the local white population, which the former defended as obligatory since white South West Africans were taxed the heaviest.
A vaccine licensure occurs after the successful conclusion of the development cycle and further the clinical trials and other programs involved through Phases I–III demonstrating safety, immunoactivity, immunogenetic safety at a given specific dose, proven effectiveness in preventing infection for target populations, and enduring preventive effect (time endurance or need for revaccination must be estimated). Because preventive vaccines are predominantly evaluated in healthy population cohorts and distributed among the general population, a high standard of safety is required. As part of a multinational licensing of a vaccine, the World Health Organization Expert Committee on Biological Standardization developed guidelines of international standards for manufacturing and quality control of vaccines, a process intended as a platform for national regulatory agencies to apply for their own licensing process. Vaccine manufacturers do not receive licensing until a complete clinical cycle of development and trials proves the vaccine is safe and has long-term effectiveness, following scientific review by a multinational or national regulatory organization, such as the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA). Upon developing countries adopting WHO guidelines for vaccine development and licensure, each country has its own responsibility to issue a national licensure, and to manage, deploy, and monitor the vaccine throughout its use in each nation.
On 2 August, Sanlu's Board decided to issue a trade recall to the wholesalers but did not notify them that the product was contaminated; however, Shijiazhuang's deputy mayor, who was invited to attend, rejected trade recall and instructed the Board to "shut the mouths of the victims by money", "wait until the end of 2008 Beijing Olympics to end smoothly and then the provincial police would hunt the perpetrators". New Zealand dairy giant Fonterra, which owned a 43% stake in Sanlu, were alerted to the contamination on 2 August. Fonterra alerted the New Zealand government and the NZ government confronted the Chinese government on 8 September. The Chinese government made the scandal public on 13 September. After the initial focus on Sanlu, further government inspections revealed that products from 21 other companies were also tainted, including those from Arla Foods–Mengniu, Yili, and Yashili. While more and more cases reached hospitals around the nation from December 2007, the first report to the government by any hospital was made on 16 July. The issue raised concerns about food safety and political corruption in China and damaged the reputation of the country's food exports. The World Health Organization called the incident "deplorable" and at least 11 foreign countries halted all imports of Chinese dairy products.
Sources: en.wikipedia.org
The map passed the Maryland House of Delegates by a 99–37 vote on February 2, 2026, but died in the Maryland Senate after Senate President Bill Ferguson refused to hold a vote on the redistricting bill in the Senate. In March 2026, a spokesperson for Moore said he supported a compromise proposal that would create a referendum to amend the Constitution of Maryland to clarify that its rules about redistricting only apply to state legislative districts and not congressional districts. However, this compromise was rejected by Ferguson, who said the Senate would prioritize other issues with the remainder of the 2026 legislative session. The Maryland General Assembly adjourned sine die on April 13, 2026, without passing a new congressional redistricting map. In July 2026, leaders of the Maryland General Assembly announced that the legislature would convene for a special session on redistricting following the U.S. Supreme Court's decision in Louisiana v. Callais. During the special session, the General Assembly passed a constitutional amendment that would exempt Maryland's congressional districts from redistricting guidelines in the state constitution, which Moore signed into law in August 2026.
=== Cell signaling and function === As a cell adhesive substrate, CCN1 induces the activation of focal adhesion kinase, paxillin, RAC, and sustained activation of MAPK/ERK1-2. In macrophages, CCN1 also activates the transcription factor NFκB and stimulates M1 polarization. CYR61 activates Akt signaling in thymic epithelial cells, promoting their proliferation and thus thymic size growth. CCN1 has potent angiogenic activity upon endothelial cells and induces neovascularization, first demonstrated in a corneal micropocket implant assay and subsequently confirmed in a rabbit ischemic hindlimb model. CCN1 also accelerates and promotes the chondrogenic differentiation of mouse limb bud mesenchymal cells, and stimulates osteoblast differentiation but inhibits osteoclastogenesis. CCN1 is a strong inducer of reactive oxygen species accumulation in fibroblastic cells, and this activity underlies many CCN1-induced apoptosis and senescence. CYR61 is able to support cell adhesion, stimulate cell migration, promote growth factor-induced cell proliferation and differentiation in some cell types, promote apoptosis in synergy with TNF family cytokines, and induce cellular senescence in fibroblasts.
The government claims modern retail will create 4 million new jobs. This cannot be true because Walmart, with over 9000 stores worldwide, has only 2.1 million employees. By allowing modern retail there could be more stores in total than Walmart has over the world, it's not unfeasible for 20,000 stores in India which would indeed create more than 4 million jobs. Let's not forget that India has ~3 times the population of the United States. The Democratic staff of the U.S. House Committee on Education and the Workforce Report- Wal-Mart's low wages and their effect on taxpayers and economic growth. Supporters claim none of these objections has merit. They claim:
Sources: en.wikipedia.org
Pharmacological stimulation of arteriogenesis, important for the treatment of arterial occlusive diseases, seems feasible with NO donors." Kolibash's 1982 study of the effect of collaterals on rest and stress myocardial perfusion, left ventricular function, and myocardial infarction prevention was most influential in turning the tide of professional opinion toward acknowledging the impact of these vessels on the jeopardized heart. In 91 patients examined by angiography, 90% of which had exertional angina, Kolibash discovered 110 occluded LAD and RCA vessels, 101 of which showed evidence of collateral vessels in their proximal areas. Kolibash divided these 101 proximal areas into two groups: those with normal perfusion at rest (43) and those with abnormal perfusion at rest (58). Wall motion abnormalities were significantly less evident in areas with normal rest perfusion—only 35% of these areas showed decreased segment shortening. By comparison, 72% of areas with abnormal rest perfusion showed decreased segment shortening. Infarctions also occurred less often in the normals than in the abnormals (12% vs. 62%). Examining four variables—rest perfusion, stress perfusion, wall motion abnormalities, and EKG evidence of MI, Kolibash found that 86% of the variables were normal in the normal perfusion group and 81% of the variables were abnormal in the abnormal perfusion group.
=== MC1R and infection/inflammation === The involvement of MC1R in a rat model of Candida albicans vaginitis was investigated. These authors suggest that MC1R is important in anti-fungal and anti-inflammatory processes, in part because siRNA knockdown of MC1R almost completely prevented the responses. Nosocomial infections are of variable importance. One of the most important is complicated sepsis, which was defined as sepsis with organ dysfunction. One variant of MC1R (MC1RR163Q, rs885479) was reported to be associated with lowered risk of developing complicated sepsis during hospitalization after trauma. Thus, if the association is confirmed, MC1R targeting may become a therapeutic option to prevent severe sepsis.
=== Bulgarian === The Bulgarian online etymological dictionary claims that longest word in Bulgarian to be the 39-letter-long непротивоконституционствувателствувайте (neprotivokonstitutsionstvuvatelstvuvayte), introduced in the Constitution of Bulgaria of 1947 (Dimitrov Constitution). The word means "do not perform actions against the constitution" (addressed to more than one person).
The simplest way to do this is to remove the gene and see what phenotype develops compared to the wild type form. Any differences are possibly the result of the missing gene. Unlike mutagenisis, genetic engineering allows targeted removal without disrupting other genes in the organism. Some genes are only expressed in certain tissues, so reporter genes, like GUS, can be attached to the gene of interest allowing visualization of the location. Other ways to test a gene is to alter it slightly and then return it to the plant and see if it still has the same effect on phenotype. Other strategies include attaching the gene to a strong promoter and see what happens when it is overexpressed, forcing a gene to be expressed in a different location or at different developmental stages.
Sources: en.wikipedia.org
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.
The number is an internal laboratory designation from the research group that first described the fragment. It does not encode a molecular weight, a receptor target, or a measured biological effect, and it carries no meaning outside the naming history of the compound.
It contains fifteen amino acid residues and has a calculated mass of roughly 1419.5 daltons. That places it in the short-peptide range, well below the size of small proteins, which affects how it is synthesized, purified, and analyzed.
The dry powder is the stable form and the dissolved form is comparatively fragile. Freezing a solution slows degradation but does not stop it, and repeated freezing and thawing adds further stress. Many laboratories therefore prepare small single-use portions rather than storing one large volume.